AR129504A2 - Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas - Google Patents
Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticasInfo
- Publication number
- AR129504A2 AR129504A2 ARP230101396A ARP230101396A AR129504A2 AR 129504 A2 AR129504 A2 AR 129504A2 AR P230101396 A ARP230101396 A AR P230101396A AR P230101396 A ARP230101396 A AR P230101396A AR 129504 A2 AR129504 A2 AR 129504A2
- Authority
- AR
- Argentina
- Prior art keywords
- dihydrochloride hydrate
- omecamtiv mecarbil
- mecarbil dihydrochloride
- omecamtiv
- crystalline form
- Prior art date
Links
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 title abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- RFUBTTPMWSKEIW-UHFFFAOYSA-N omecamtiv mecarbil Chemical compound C1CN(C(=O)OC)CCN1CC1=CC=CC(NC(=O)NC=2C=NC(C)=CC=2)=C1F RFUBTTPMWSKEIW-UHFFFAOYSA-N 0.000 abstract 12
- 229950001617 omecamtiv mecarbil Drugs 0.000 abstract 12
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 229910002483 Cu Ka Inorganic materials 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 239000000945 filler Substances 0.000 abstract 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229960001021 lactose monohydrate Drugs 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Hidrato de diclorhidrato de omecamtiv mecarbil. Reivindicación 2: El hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizado porque el hidrato de diclorhidrato de omecamtiv mecarbil es un monohidrato. Reivindicación 3: Una forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizada porque la forma cristalina se caracteriza por un patrón de difracción en polvo de rayos X que comprende picos en 6,6, 14,9, 20,1, 21,4, y 26,8 ± 0,2º 2q utilizando radiación Cu Ka. Reivindicación 7: Una forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizada porque el hidrato de diclorhidrato de omecamtiv mecarbil se caracteriza por un patrón de difracción en polvo de rayos X que comprende picos en 6,6, 8,4, 14,9, 15,4 y 26,8 ± 0,2º 2q utilizando radiación Cu Ka. Reivindicación 10: Una forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1, caracterizada porque el hidrato de diclorhidrato de omecamtiv mecarbil se caracteriza por un patrón de difracción en polvo de rayos X que comprende picos en 6,6, 14,9, 16,3, 19,5 y 26,8 ± 0,2º 2q utilizando radiación Cu Ka. Reivindicación 12: Una composición farmacéutica caracterizada porque comprende el hidrato de diclorhidrato de omecamtiv mecarbil de la reivindicación 1 o 2, o la forma cristalina del hidrato de diclorhidrato de omecamtiv mecarbil de conformidad con cualquiera de las reivindicaciones 3 - 11. Reivindicación 13: Una composición farmacéutica caracterizada porque comprende: 6,13 - 18,37% p/p de un hidrato de diclorhidrato de omecamtiv mecarbil; 25 - 30% p/p de un agente de liberación de control, en donde el agente de liberación de control es hidroxipropilmetilcelulosa; 7,66 - 18,37% p/p de un agente de modificación de pH que es ácido fumárico; y 32,27 - 60,21% p/p de un relleno, en donde el relleno es una combinación de celulosa microcristalina y monohidrato de lactosa. Reivindicación 14: La composición farmacéutica de conformidad con la reivindicación 13, caracterizada porque tiene una relación en peso del agente modificador del pH al hidrato de diclorhidrato de omecamtiv mecarbil de menos de 2:1 a 1:1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785763P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129504A2 true AR129504A2 (es) | 2024-09-04 |
Family
ID=50549466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101155A AR095542A1 (es) | 2013-03-14 | 2014-03-14 | Compuestos heterocíclicos y sus usos |
| ARP230101396A AR129504A2 (es) | 2013-03-14 | 2023-06-01 | Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101155A AR095542A1 (es) | 2013-03-14 | 2014-03-14 | Compuestos heterocíclicos y sus usos |
Country Status (42)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035525A (zh) | 2004-06-17 | 2007-09-12 | 赛特凯恩蒂克公司 | 用于治疗心脏疾病的经取代的脲衍生物 |
| HK1218080A1 (zh) | 2013-03-14 | 2017-02-03 | Amgen Inc. | 雜環化合物和其用途 |
| TWI790189B (zh) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| JP6858716B2 (ja) * | 2015-06-26 | 2021-04-14 | アムジエン・インコーポレーテツド | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 |
| CN110996953A (zh) | 2017-06-30 | 2020-04-10 | 安进公司 | 用心脏肌小节激活剂治疗心力衰竭的方法 |
| CN110799503B (zh) | 2017-06-30 | 2023-06-27 | 美国安进公司 | 美卡奥美坎替的合成 |
| EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
| HUE052049T2 (hu) * | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| JP2021534138A (ja) * | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EA202192453A1 (ru) * | 2019-03-12 | 2021-12-03 | Амген Инк. | Полиморфы и сокристаллы активатора кардиотропонина |
| WO2020185983A1 (en) * | 2019-03-12 | 2020-09-17 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041198A4 (en) * | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| IL295490A (en) | 2020-02-10 | 2022-10-01 | Amgen Inc | omecamtiv mecarbil tablet |
| JP2022039996A (ja) * | 2020-08-26 | 2022-03-10 | アムジエン・インコーポレーテツド | Ｍｃｌ－１阻害剤処方物 |
| US12194039B2 (en) | 2020-11-12 | 2025-01-14 | Amgen Inc | Methods of treating heart failure by administering omecamtiv mecarbil |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| CA3212491A1 (en) | 2021-03-10 | 2022-09-15 | Sebastien Caille | Synthesis of omecamtiv mecarbil |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2788775B1 (fr) | 1999-01-22 | 2001-04-13 | Pf Medicament | Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique |
| JP4100910B2 (ja) | 1999-12-23 | 2008-06-11 | ファイザー・プロダクツ・インク | ヒドロゲル駆動の薬物剤形 |
| GB0124455D0 (en) | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
| MXPA04003022A (es) | 2001-10-17 | 2004-07-05 | Aventis Pharma Gmbh | Metodo para reducir diabetes tipo 2 en pacientes de alto riesgo. |
| US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| CN101035525A (zh) | 2004-06-17 | 2007-09-12 | 赛特凯恩蒂克公司 | 用于治疗心脏疾病的经取代的脲衍生物 |
| WO2007054975A1 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
| TW200738243A (en) * | 2005-11-15 | 2007-10-16 | Glaxo Group Ltd | Novel process and formulations |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| AR058347A1 (es) | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
| US7989455B2 (en) * | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7639112B2 (en) | 2007-04-25 | 2009-12-29 | Sony Corporation | Fuse device with integrated switch |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| EP3269374B1 (en) | 2008-10-03 | 2020-08-26 | ViCardia Therapeutics, Inc. | Aica riboside analogs for treatment of acute decompensated heart failure |
| US9253433B2 (en) | 2012-11-27 | 2016-02-02 | International Business Machines Corporation | Method and apparatus for tagging media with identity of creator or scene |
| HK1218080A1 (zh) * | 2013-03-14 | 2017-02-03 | Amgen Inc. | 雜環化合物和其用途 |
| CA2902424A1 (en) * | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| JP6858716B2 (ja) | 2015-06-26 | 2021-04-14 | アムジエン・インコーポレーテツド | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 |
| CN110799503B (zh) | 2017-06-30 | 2023-06-27 | 美国安进公司 | 美卡奥美坎替的合成 |
| CN110996953A (zh) * | 2017-06-30 | 2020-04-10 | 安进公司 | 用心脏肌小节激活剂治疗心力衰竭的方法 |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| JP2021534138A (ja) | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041710A1 (en) | 2019-10-09 | 2022-08-17 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| EP4041198A4 (en) | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| IL295490A (en) | 2020-02-10 | 2022-10-01 | Amgen Inc | omecamtiv mecarbil tablet |
| US12194039B2 (en) | 2020-11-12 | 2025-01-14 | Amgen Inc | Methods of treating heart failure by administering omecamtiv mecarbil |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| CA3212491A1 (en) | 2021-03-10 | 2022-09-15 | Sebastien Caille | Synthesis of omecamtiv mecarbil |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2014
- 2014-03-14 HK HK16106250.4A patent/HK1218080A1/zh unknown
- 2014-03-14 KR KR1020227007907A patent/KR102474467B1/ko active Active
- 2014-03-14 AR ARP140101155A patent/AR095542A1/es not_active Application Discontinuation
- 2014-03-14 AU AU2014240049A patent/AU2014240049C1/en active Active
- 2014-03-14 SG SG11201507258PA patent/SG11201507258PA/en unknown
- 2014-03-14 BR BR112015023417-8A patent/BR112015023417B1/pt active IP Right Grant
- 2014-03-14 SI SI201431724T patent/SI2968173T1/sl unknown
- 2014-03-14 PE PE2015002000A patent/PE20151786A1/es unknown
- 2014-03-14 DK DK14719472.4T patent/DK2968173T3/da active
- 2014-03-14 JP JP2016502336A patent/JP6498658B2/ja active Active
- 2014-03-14 US US14/210,713 patent/US9951015B2/en active Active
- 2014-03-14 AP AP2015008789A patent/AP2015008789A0/xx unknown
- 2014-03-14 CA CA3147180A patent/CA3147180C/en active Active
- 2014-03-14 CA CA2902646A patent/CA2902646C/en active Active
- 2014-03-14 MX MX2015012429A patent/MX2015012429A/es unknown
- 2014-03-14 PT PT147194724T patent/PT2968173T/pt unknown
- 2014-03-14 HR HRP20191728 patent/HRP20191728T1/hr unknown
- 2014-03-14 MX MX2015012414A patent/MX363347B/es unknown
- 2014-03-14 MA MA44637A patent/MA44637B1/fr unknown
- 2014-03-14 EP EP14719472.4A patent/EP2968173B1/en active Active
- 2014-03-14 PT PT147203699T patent/PT2970123T/pt unknown
- 2014-03-14 RS RS20191313A patent/RS59536B1/sr unknown
- 2014-03-14 CN CN201480018405.6A patent/CN105209437B/zh active Active
- 2014-03-14 AU AU2014239995A patent/AU2014239995B2/en active Active
- 2014-03-14 SG SG10201706656RA patent/SG10201706656RA/en unknown
- 2014-03-14 UA UAA201509685A patent/UA117011C2/uk unknown
- 2014-03-14 CN CN201810812212.8A patent/CN108785265B/zh active Active
- 2014-03-14 EP EP20201011.2A patent/EP3821882A1/en active Pending
- 2014-03-14 ES ES14719472T patent/ES2837038T3/es active Active
- 2014-03-14 JP JP2016502348A patent/JP6783138B2/ja active Active
- 2014-03-14 PL PL14719472T patent/PL2968173T3/pl unknown
- 2014-03-14 ES ES14720369T patent/ES2750676T3/es active Active
- 2014-03-14 SM SM20190563T patent/SMT201900563T1/it unknown
- 2014-03-14 KR KR1020157025283A patent/KR102374159B1/ko active Active
- 2014-03-14 MA MA38399A patent/MA38399B2/fr unknown
- 2014-03-14 WO PCT/US2014/027104 patent/WO2014152236A1/en not_active Ceased
- 2014-03-14 DK DK14720369.9T patent/DK2970123T3/da active
- 2014-03-14 SI SI201431358T patent/SI2970123T1/sl unknown
- 2014-03-14 RS RS20201513A patent/RS61215B1/sr unknown
- 2014-03-14 TW TW103109296A patent/TWI667026B/zh active
- 2014-03-14 NZ NZ711225A patent/NZ711225A/en unknown
- 2014-03-14 HU HUE14719472A patent/HUE052355T2/hu unknown
- 2014-03-14 WO PCT/US2014/027146 patent/WO2014152270A1/en not_active Ceased
- 2014-03-14 EP EP14720369.9A patent/EP2970123B2/en active Active
- 2014-03-14 PH PH1/2019/500176A patent/PH12019500176B1/en unknown
- 2014-03-14 ME MEP-2019-283A patent/ME03566B/me unknown
- 2014-03-14 CN CN201480014897.1A patent/CN105120844A/zh active Pending
- 2014-03-14 HR HRP20201967TT patent/HRP20201967T1/hr unknown
- 2014-03-14 PL PL14720369T patent/PL2970123T3/pl unknown
- 2014-03-14 RU RU2015143643A patent/RU2663663C2/ru active
- 2014-03-14 UY UY0001035449A patent/UY35449A/es active IP Right Grant
- 2014-03-14 HU HUE14720369A patent/HUE046285T2/hu unknown
- 2014-03-14 LT LT14720369T patent/LT2970123T/lt unknown
- 2014-03-14 MY MYPI2015002299A patent/MY186048A/en unknown
- 2014-03-14 SM SM20200685T patent/SMT202000685T1/it unknown
- 2014-03-14 MY MYPI2019004869A patent/MY204971A/en unknown
- 2014-03-14 LT LTEP14719472.4T patent/LT2968173T/lt unknown
- 2014-03-14 US US14/773,436 patent/US9988354B2/en active Active
- 2014-03-14 BR BR112015022857-7A patent/BR112015022857B1/pt active IP Right Grant
- 2014-03-14 EA EA201591728A patent/EA031185B1/ru unknown
- 2014-03-16 JO JOP/2014/0114A patent/JOP20140114B1/ar active
-
2015
- 2015-08-24 IL IL240788A patent/IL240788B/en active IP Right Grant
- 2015-08-31 TN TN2015000380A patent/TN2015000380A1/en unknown
- 2015-09-03 IL IL24108915A patent/IL241089B/en active IP Right Grant
- 2015-09-08 PH PH12015501998A patent/PH12015501998A1/en unknown
- 2015-09-11 MX MX2021001231A patent/MX2021001231A/es unknown
- 2015-09-14 CL CL2015002708A patent/CL2015002708A1/es unknown
- 2015-09-14 SA SA515361088A patent/SA515361088B1/ar unknown
- 2015-10-13 CR CR20150549A patent/CR20150549A/es unknown
-
2018
- 2018-03-20 US US15/926,411 patent/US10421726B2/en active Active
- 2018-04-26 US US15/963,529 patent/US20180312469A1/en not_active Abandoned
- 2018-11-15 JP JP2018214801A patent/JP6689942B2/ja active Active
-
2019
- 2019-09-23 US US16/579,360 patent/US11384053B2/en active Active
- 2019-10-15 CY CY20191101080T patent/CY1122695T1/el unknown
- 2019-11-14 US US16/684,216 patent/US20200079736A1/en not_active Abandoned
-
2020
- 2020-04-08 JP JP2020069487A patent/JP6966590B2/ja active Active
- 2020-07-02 US US16/920,144 patent/US11472773B2/en active Active
- 2020-07-02 US US16/920,155 patent/US20200331859A1/en not_active Abandoned
- 2020-12-15 CY CY20201101184T patent/CY1123633T1/el unknown
-
2021
- 2021-09-24 US US17/448,833 patent/US11958809B2/en active Active
- 2021-10-21 JP JP2021172324A patent/JP7174132B2/ja active Active
-
2022
- 2022-06-08 US US17/806,033 patent/US11884630B2/en active Active
- 2022-09-08 US US17/930,695 patent/US20230044617A1/en not_active Abandoned
-
2023
- 2023-06-01 AR ARP230101396A patent/AR129504A2/es unknown
- 2023-11-27 US US18/520,156 patent/US12221417B2/en active Active
- 2023-12-06 US US18/531,424 patent/US12275704B2/en active Active
-
2024
- 2024-01-24 US US18/421,849 patent/US20240317687A1/en active Pending
- 2024-12-20 US US18/990,483 patent/US20250243163A1/en active Pending
-
2025
- 2025-01-17 US US19/029,911 patent/US20250376444A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129504A2 (es) | Hidrato de diclorhidrato de omecamtiv mecarbil, formas cristalinas, y composiciones farmacéuticas | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX363456B (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX2017007299A (es) | Composiciones en suspension de liberacion prolongada gastroretentivas. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MY186133A (en) | Tgf-? inhibitors | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2018005708A (es) | Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7. | |
| MX2017002028A (es) | Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7). | |
| PH12016500756A1 (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| AR094842A1 (es) | Formas sólidas de un inhibidor cdk4/6 selectivo | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| WO2014197093A3 (en) | All water-based nanopatterning | |
| MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| GT201500247A (es) | Imidazopiridazinas sustituidas | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
| BR112015023351A2 (pt) | forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio | |
| PL408608A1 (pl) | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| MX2016013561A (es) | Activadores de herg policiclicos. |